ENGAGE
ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.
Overview
One of two large aducanumab trials. ENGAGE did not meet its primary endpoint. The later US accelerated approval was withdrawn. Failure trials belong in a map so positive trials are not the only story.
- Numbers are not recorded here for this endpoint. Aducanumab: Did not meet the primary endpoint as designed; Placebo.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Early Alzheimer’s disease. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Similar pages
not linked directly; found by shared links- TrialEXPEDITION 3
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Aducanumab, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentRemternetug
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TrialCLARITY AD
Shares Biogen, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentLecanemab
Shares Biogen, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.
- TreatmentBrexpiprazole
Shares Alzheimer’s disease and the tag dementia-atlas.